On this page
What should the CTD A.1 facilities and equipment appendix explain?
For the applicable product and facility context, show the relevant manufacturing layout, material and personnel movement, equipment use and contamination-prevention arrangements. Reconcile the description with the actual process and current facility records. A.1 is a scoped technical account, not a generic site brochure or a substitute for every regional facility requirement.
Before you begin
M4Q(R1) A.1 specifically describes biotech facility/equipment information. The appendix family also includes separate agent-safety and novel-excipient tasks.
What you will prepare: A facility narrative and annotated flow map that reconcile with the proposed process and shared-area controls.
Sections covered in this guide (2)
Choose the appendix by its actual purpose
The 3.2.A family is not a place for miscellaneous unplaced documents. A.1 addresses the relevant facility/equipment information, A.2 the adventitious-agent safety assessment, and A.3 novel-excipient detail. Route each item according to its purpose and link it to the S or P narrative that relies on it.
For A.1, establish the product, manufacturing sites, operations and whether the biotech facility context described by M4Q applies. Other product classes may have regional or product-specific facility expectations; this heading alone cannot decide them. Ask the regulatory/manufacturing owners to resolve the scope rather than assuming every chemical product needs the same appendix.
Show movement and shared-area context
Obtain current facility drawings and process descriptions. Prepare a diagram showing the relevant movement of raw materials, personnel, waste and intermediates into and out of manufacturing areas. Explain adjacent areas that could affect product integrity. Identify other developmental or approved products handled in the same areas as described by M4Q, using controlled manufacturing records rather than an outdated site brochure.
Pair the diagram with a narrative so readers can understand crossings, transfers and separation measures. Reconcile room names and process steps with S.2/P.3. Where a planned layout differs from the layout supporting the evidence, identify the difference and obtain its assessment; do not present a future state as already established.
Explain equipment use and contamination prevention
Describe relevant product-contact equipment and whether it is dedicated or shared. Present applicable preparation, cleaning, sterilization and storage information, along with facility design and operating measures used to prevent contamination or cross-contamination. Tie statements to actual procedures and the supporting technical records; do not claim validation from the presence of an SOP number alone.
Fictional exercise: the narrative says an equipment train is dedicated, while the current scheduling record shows another product using it. Resolve the factual use pattern and obtain the manufacturing/quality assessment of the applicable controls. Update the narrative and cross-references only after that determination. Renaming the equipment “dedicated during use” would hide the underlying issue rather than resolve it.
Connect the facility drawing to the manufacturing narrative
A facility diagram is useful only when its labels and movements can be followed into the process description. Use this editorial crosswalk with manufacturing and quality reviewers.
| Facility element | Information to reconcile | Review question |
|---|---|---|
| Rooms and areas | Current drawing and process operations | Do names and locations match S.2/P.3? |
| Material movement | Entry, transfer, storage and waste routes | Are crossings and protective controls explained? |
| Personnel movement | Relevant access and operational patterns | Does the diagram reflect actual practice? |
| Equipment train | Product contact and dedicated/shared use | Is the stated use pattern supported by records? |
| Preparation and cleaning | Applicable procedures and technical evidence | Does the claimed control exceed what is established? |
Describe a planned layout as planned. Identify the differences from the configuration supporting the current evidence and obtain the appropriate assessment. A drawing revision date alone does not show that an altered manufacturing arrangement has been implemented or evaluated.
Review exercise: a cleaning procedure exists, but its scope names a different equipment configuration from the dossier diagram. Identify the difference and ask the quality and manufacturing owners what evidence supports the proposed use. Neither adding the SOP number nor renaming the equipment closes that gap.
Link the resolved account to substance manufacturing or product manufacturing. Where shared areas affect the agent-safety assessment, make the factual relationship consistent across the documents.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does every chemical product need the same A.1 appendix as a biotechnology product?
Do not assume identical scope from the heading alone. M4Q describes a biotechnology facility context for A.1; other expectations may depend on the region and product. Establish the applicable purpose with the regulatory and manufacturing owners before copying a generic facility package.
Does an SOP reference prove that cleaning is validated?
No. A procedure describes an activity, while evidence of an applicable evaluation or validation supports a particular conclusion. Confirm the equipment, process and scope covered by the records. The presence of a procedure number alone cannot establish the claimed level of demonstration.
Can equipment be called dedicated when other products use it?
Describe the actual use pattern and obtain the relevant assessment of shared-use controls. Qualifying the wording to conceal a contradictory schedule does not resolve the factual issue. Reconcile the narrative with controlled manufacturing records and the evidence supporting contamination prevention.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
ICH M4Q(R1): CTD Quality ↗Step 4, September 12, 2002; Module 3, printed pages 5–18. Organization/content guidance, not a universal list of required studies. Checked September 22, 2026. Guide-specific passages: 3.2.A.1, printed page 16; appendix context pages 16–17.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 3.2.A.1. A heading identifies placement, not mandatory applicability.